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Objectives: To characterize and compare cancer survival among HIV-infected and –
uninfected individuals diagnosed with cancer in the pre-HAART (1984-1994) and the 
HAART (1995-2013) eras, and to describe cancer survival in the HAART era by HIV 
status and use of HAART. 
Design: A prospective cohort study nested within the Multicenter AIDS Cohort (MACS) 
and Women’s Interagency HIV Study (WIHS).  
Study Participants: We studied 911 individuals from the time of cancer diagnosis until 
the earliest of death or the last study visit attended. Only the initial primary cancers that 
were diagnosed after enrollment in the MACS or WIHS were included. Second primaries 
and subsequent metastases were not considered in the analysis. Participants with an 
unknown cancer diagnosis date were excluded, as were participants with more than a 2-
year gap between their last visit prior to cancer diagnosis and the diagnosis date, 
participants whose SEER Site ICD-0-3 cancer code was an epithelial-cell skin cancer, 
and those with less than 24 hours of follow-up. 
Methods: Cox regression was used to calculate adjusted hazard ratios of death. The 
proportional hazard assumption was assessed using complementary log-log regression 
plots and by fitting unadjusted Cox time-dependent Relative Hazards models.  
Results: Among MACS participants, HIV-infected individuals with cancers diagnosed in 
the HAART era compared to those diagnosed in the pre-HAART era had better survival, 
and the difference between these two groups increased with time following cancer 
diagnosis. There was no significant difference in survival in the HAART era comparing 
HIV-infected and HIV-uninfected individuals (adjusted HR: 0.70; 95% CI: 0.35 – 1.38). 
Survival did not differ for HIV-infected individuals diagnosed with ADMs as compared 
 
 iii 
to those diagnosed with NADMs in the HAART era, but individuals taking HAART at 
the visit prior to cancer diagnosis had a lower hazard of death than did those not taking 
HAART (p = 0.03). Interestingly, we also found that HAART use was associated with 
survival (adjusted HR: 0.36, 95% CI: 0.19 – 0.69) for individuals diagnosed with 
infection-related cancers, but not among those diagnosed with non-infection-related 
cancers (adjusted HR: 1.07, 95% CI: 0.67 – 1.72).  
Conclusions: The results of this study demonstrate that HAART use prior to diagnosis 
with infection-related cancers among HIV-infected individuals is associated with 
improved survival, but this was not the case for non-infection-related cancers. Future 
research should further assess the survival benefit of HAART for individual infection-
related cancers to determine whether our finding is generally relevant for all cancers in 
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Cancer refers to a group of heterogeneous diseases of genetic origin that are 
characterized by uncontrolled cell growth and division that result from mutations in 
several genes: oncogenes, tumor-suppressor genes, and stability genes (1,2).  It is thought 
that the risk of uncontrolled cell growth and proliferation has been present since the 
existence of metazoans, and that natural defenses against cancer evolved simultaneously 
with increased organism complexity (3). 
In the United States, an estimated 1.7 million incident cases of cancer were 
identified in 2014, and cancer remains the second leading cause of death in the United 
States, following heart disease, with an estimated 585,720 cancers deaths occurring in 
2014 (4,5). With increased awareness about risk factors for certain cancers, public health 
interventions have been successfully implemented, resulting in decreased incidence and 
mortality rates for certain cancers such as lung cancer (6). However, the incidence for 
other cancer types, particularly several infection-related cancers (such as liver and oral 
cancers), remains on the rise (6).       
1.1.2 Etiology and Progression 
Oncogenes (cancer-inducing genes) become activated when they mutate due to 
one of three mechanisms (chromosomal translocations, gene amplifications, or certain 
intragenic mutations) that leads to overexpression (1,3). This activation promotes cell 
proliferation since, when this occurs, normal signaling is disrupted and oncoproteins 
release an excess of growth-stimulating signals (3). Conversely, mutations in tumor 
suppressor genes, whose role it is to regulate cell proliferation, cause gene inactivation
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 (1,3). Typically, mutations in both copies of a tumor suppressor gene are required to 
impact the cell phenotype (3). Together, mutations in these two classes of genes 
contribute to tumor growth and progression by promoting cell birth and preventing cell 
death (1). Stability genes, such as mismatch repair, nucleotide-excision repair, and base-
excision repair genes, repair errors in DNA replication, and thereby reduce the rate of 
genetic mutations (1). When stability genes are mutated, they become inactivated, and 
their capacity to repair becomes impaired (1).  
Tumorigenesis can be triggered when a mutation in a gatekeeping pathway occurs 
in a cell that has the capacity to replicate; such a mutation gives the cell a selective 
proliferative advantage (1). As the majority of cancers have a late onset, with the median 
age at diagnosis being 66 years, this suggests that tumor progression is a gradual process, 
and that many cancers require decades to develop (3,5). The transition from a primary 
tumor to an invasive and metastatic tumor is a multi-stage process called the “the 
invasion metastasis cascade” that involves breaching the basement membrane, invading 
the lymphatic or blood microvessels, transportation of cancer cells through the circulatory 
system, and eventual colonization at another site (3).   
1.1.3 Classification and Staging 
 Cancer classification is based on the histology and the primary site (7). Cancers 
are classified as carcinomas, sarcomas, myelomas, leukemia, lymphomas or cancers of 
mixed histology (7). The vast majority of cancers (80 – 90%) are carcinomas, which are 
malignancies that arise in epithelial tissue or in tissue linings of the body (7).     
Cancer staging refers to describing the severity of the disease and is vital for 
treatment decisions and estimating a patient’s prognosis (8). Staging is determined at 
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diagnosis and involves consideration of the primary site, cell type, lymph node 
involvement, and tumor size and extent, number (if metastases are present), and grade 
(8). A commonly used staging system is the TNM system, which describes the primary 
tumor (T), regional lymph node involvement (N), and the presence of distant metastasis 
(M) (8). In order to determine staging, patients typically undergo physical exams, 
imaging studies, lab tests, and, if appropriate, biopsies (8). 
1.1.4 Clinical Manifestation and Treatment 
 Clinical manifestation of cancer comes in many forms. Depending on the primary 
site, the tumor’s growth may lead to pressure on an organ, blood vessel, or nerve, which 
causes the patient to experience pain (9). Patients may also present with persistent 
fatigue, fever (usually following metastasis), skin changes, or unexplained weight loss, as 
the cancer cells consume a large portion of the body’s energy resources (9). At times, 
only after the tumor has become quite large do signs and or symptoms arise (9). Although 
treatment options vary by cancer type and stage, they typically involve one or more of 
surgery, radiation, and chemotherapy (10). 
1.1.5 Outcomes 
 Cancer prognosis varies greatly depending on cancer type, stage, treatment, and 
the response to treatment. At present, the Surveillance, Epidemiology, and End Results 
program (SEER) estimates that 66.1% of cancer patients (diagnosed with cancers of all 
sites) in the US survive five or more years after diagnosis; this estimate is based on data 
gathered during 2004-2010 (5).  However, certain cancers, such as pancreatic cancer have 
extremely poor 5-year survival (6.7%), while others, such as breast cancer, typically, 
have a much better prognosis (5-year survival: 89.2%) (11,12). Pancreatic cancer survival 
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is poor since diagnosis often occurs at a more advanced stage, with only 8.8% of cancers 
being detected when they are localized, as compared to breast cancer which is typically 
detected earlier (with 61% of cancers detected when they are localized) (11,12). 
Additionally, in the US, breast cancer is a common cause of cancer mortality among 
women, and there are screening programs in place to detect breast cancer early (13).    
1.1.6 Screening and Prevention 
 With greater knowledge about the natural history and risk factors for certain 
cancers, prevention and cancer screening measures have been introduced in an effort to 
reduce incidence of and mortality due to cancer (14). The US Preventative Services Task 
Force (USPSTF) evaluates the strength of evidence of interventions and reports its 
recommendations and the grade (weight of evidence) for certain cancers (15). In 
reviewing evidence and preparing recommendations, experts consider the potential 
benefits and harms of screening, the population for which screening would be most 
appropriate for, and in what settings screening should be implemented (16).       
1.1.7 Established Risk Factors for Cancer Incidence and Progression 
 Many environmental exposures have been associated with an increased risk of 
certain cancers. Cigarette smoking has been causally associated with numerous cancers, 
including lung, oral, esophageal, and pancreatic cancer (14). Other important lifestyle 
factors include nutrition, alcohol use, and physical activity (14). Some cancers are known 
to be infection-related and infection with certain agents may be necessary for 
carcinogenesis or may put an individual at increased risk. Infectious agents that have 
been associated with cancer include human papillomavirus (HPV), Epstein-Barr Virus 
(EBV), and Hepatitis B and C (14). Radiation exposure (both UV and ionizing) has also 
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been associated with increased cancer risk (14). Furthermore, immunosuppression has 
been linked to greater cancer risk (14). Organ transplant recipients and patients living 
with HIV/AIDS, two populations whose main shared risk factor is immunodeficiency, 
have been shown to have similar patterns of increased cancer risk (17).    
1.2 The Impact of HAART on the Relationship of Cancer and HIV 
1.2.1 Introduction  
 There has been a relationship between cancer and HIV since the start of the 
Acquired Immunodeficiency Syndrome (AIDS) pandemic, when it was noted that HIV-
infected individuals had a higher incidence of three cancers: Kaposi’s sarcoma (KS), non-
Hodgkin’s lymphoma (NHL), and invasive cervical cancer (ICC) (18).  Since AIDS was 
first recognized in the 1980s, an estimated 60 million individuals have been infected with 
Human Immunodeficiency Virus (HIV) the virus that causes AIDS (19). AIDS has led to 
the deaths of 25 million individuals, and remains a public health concern as over 33 
million individuals worldwide are HIV-infected currently (19). HIV/AIDS research has 
led to the characterization of HIV and its pathogenesis as well as successful therapeutic 
interventions, e.g., Highly Active Antiretroviral Therapy (HAART), and strategies to 
decrease the likelihood of HIV transmission (19). Since the introduction of HAART, 
trends in cancer incidence among HIV-infected have changed dramatically (18).  
1.2.2 Impact of HAART on Cancer Incidence 
 Introduced in the mid-1990s, HAART has the capacity to alter the natural history 
of HIV by suppressing HIV replication and to thereby drastically extend the lifespan of 
seropositive individuals; whereas prior to HAART, once diagnosed with AIDS, 
individuals typically survived only a few weeks or months following diagnosis, today, a 
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near-normal life expectancy can often be achieved with HAART initiation earlier in the 
disease process (19,20). The use of HAART has been associated with dramatic declines 
in the incidence of the AIDS-defining malignancies (ADMs) KS and NHL and a rise in 
certain non-ADMs (NADMs) among HIV-infected individuals (20–22). Although 
HAART has certainly played a substantial role in the changes in cancer incidence 
observed, it is unclear to what degree its relationship with behavioral risk factors, viral 
co-infections, and other factors has also contributed to the cancer trends (20). The 
introduction of HAART has also impacted mortality due to cancer. Whereas in the pre-
HAART era cancer-related deaths accounted for 10% of deaths among HIV-infected 
individuals, at present approximately 30% of all deaths in HIV-infected individuals are 
cancer-related, which makes cancer prevention and treatment research in this population 
of great importance (23,24). 
In the pre-HAART era, it was noted that certain cancers were more common 
among individuals living with AIDS. These were KS, NHL, and ICC (23); these cancers 
became known as ADMs when they arose in seropositive individuals. Studies have 
shown that “HIV-infected individuals have a 3640-fold increased risk of KS caused by 
human herpesvirus 8 (HHV8), a 77-fold increased risk of NHL, some of which are 
caused by Epstein-Barr virus (EBV), and a six-fold increased risk of cervical cancer 
caused by oncogenic subtypes of human papilloma virus (HPV)” relative to the general 
population (25). Population-based registry data has been used to estimate cancer 
incidence prior to and after the introduction of HAART and to assess the impact of 
HAART on cancer risk in the United States (21). This data showed that in the pre-
HAART era, there was a very high incidence of the ADMs KS and NHL, with these 
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cancers having standardized incidence ratio (SIR) values of 52,900 and 79.8, 
respectively, for individuals with an AIDS onset during 1980-1989. However, during the 
early HAART era, there was already a substantial decline in risk relative to the pre-
HAART era; the risk of KS and NHL declined by 83.5% and 57.5%, respectively (21). 
Nonetheless, in the early HAART era (1996-2000), for many cancers, HIV-infected 
individuals diagnosed with cancer continued to have significantly worse survival relative 
to individuals in the general population who were diagnosed with cancer (26).  Late 
diagnosis among HIV-infected individuals and opportunistic infections associated with 
HIV are thought to have contributed to this observed difference in survival (26). 
 While the introduction of HAART was associated with a decline in the ADMs KS 
and NHL among HIV-infected individuals, it was also followed by a reported increase in 
certain NADMs in the HIV-infected population, such as Hodgkin’s lymphoma (HL), 
skin, colorectal, prostate, anal, lung, and renal cancer (22–24). A systematic review of the 
impact of HAART on cancer incidence among HIV-infected individuals found that there 
was an overall increased risk of developing NADMs following the introduction of 
HAART (24). This is in large part because HAART increased the lifespan of seropositive 
individuals and the risk for most malignancies increases with age (18,22,27). Seropositive 
individuals have had higher rates of NADMs than the general population does, especially 
of cancers that are either confirmed or likely to be infection-related (20,28,29). The 
greater cancer risk in HIV-infected individuals relative to that of the general population 
may be explained by the higher prevalence of traditional risk factors among seropositive 
individuals, such as cigarette smoking, viral co-infection (HPV, hepatitis B and C, HHV-
8, and EBV), and alcohol use (23,30). It has also been demonstrated that HIV infection is 
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a risk factor for lung cancer, independent of smoking status (31). Furthermore, even 
while using HAART, HIV-infected individuals continue to display persistent 
immunodeficiency, chronic inflammation, and other conditions associated with HIV 
infection (28,32).  
 Contrary to prior expectations, studies have not consistently shown an association 
between HAART use and a decreased risk of NADMs, perhaps because the role of the 
immunologic response to HAART in the HAART-NADM relationship had not been 
properly accounted for (33). Much remains to be understood about the mechanism behind 
the increased risk of certain NADMs and the role of HAART use in cancer survival (28). 
A recent study began to explore the trends in cancer incidence subsequent to the 
introduction of HAART using population-level data, and attempted to decipher to what 
degree these trends are influenced by increased lifespan, temporal trends in the general 
population, and changes in relative risk in the HIV-infected population (27). This study 
found that demographic changes as well as temporal trends in the general population had 
the greatest impact for individuals diagnosed with NADMs (27). 
1.2.3 Impact of HAART on Cancer Survival 
1.2.3.1 Cancer Survival Comparison by HIV Status and HAART Use 
 Previous studies have demonstrated that HAART use helped increase short- and 
medium-term survival among HIV-individuals diagnosed with cancer substantially, and 
thereby has diminished the difference in survival seen between HIV-infected individuals 
and the general population during the pre-HAART and early HAART eras (34). A 
population-based study conducted between 1980 and 2000 comparing the survival of 
people living with AIDS to that of the general population found that 2-year survival rate 
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after cancer diagnosis for people living with AIDS showed significant improvement since 
the introduction of HAART (35). Nonetheless the authors reported that the gap in overall 
survival between people living with AIDS and the general population persisted (35).  
 In the case of NHL, some studies have suggested that, in the HAART era, cancer 
survival is comparable for HIV-infected individuals undergoing cancer treatment while 
using HAART and HIV–uninfected individuals (36,37). However, many of these studies 
had a small and very specific study population, and so their results may not necessarily be 
generalizable (38). A larger prospective cohort study found that HIV-infected individuals 
had a greater risk of 2-year lymphoma-specific mortality than did the general population, 
and that survival was only comparable to that of the general population for individuals 
with a CD4 count of at least 200 cells/μL and no prior AIDS diagnosis (38). This finding 
should be taken with caution due to the amount of missing CD4 cell count data at the 
time of cancer diagnosis (38). A recent study also suggested that survival of HIV-infected 
individuals diagnosed with NHL still lags behind that of HIV-uninfected individuals, 
even though it has shown substantial improvement (39).  
1.2.3.2 Cancer Survival by Cancer Type: ADM vs. NADM 
Given the reported synergistic effect of HAART and chemotherapy on survival 
for individuals with NHL and KS and the direct effect of protease inhibitors (PIs) against 
KS, we would expect that survival would be better among individuals diagnosed with 
ADMs as compared to those diagnosed with NADMs (34). It has also been demonstrated 
that male gender, IDU, co-infection with hepatitis B, earlier year of cancer diagnosis, and 
non-white race/ethnicity has been associated with worse survival, following an NADM 
diagnosis (26). The literature available comparing survival of individuals diagnosed with 
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ADMs to those diagnosed with NADMs has not been conclusive. Two studies have 
reported that although HAART has improved survival for HIV-infected individuals 
diagnosed with cancer, overall survival following cancer diagnosis in the HAART era 
remains poor and does not differ significantly overall among individuals diagnosed with 
ADMs and those diagnosed with NADMs (34,40). A recent study used an Italian 
observational cohort to compare survival of seropositive individuals with ADMs to the 
survival of seropositive individuals with NADMs in the HAART era, and suggested that 
HAART has less of an effect for individuals diagnosed with NADMs than it does for 
individuals diagnosed with ADMs (41). It reported that survival two years after diagnosis 
was comparable in the two groups, but longer-term survival was worse for individuals 
diagnosed with NADMs, and depended greatly on NADM type (41).  
 In the case of NHL, simultaneous use of chemotherapy and HAART has been 
shown to improve response to chemotherapy and increase survival in HIV-infected 
individuals diagnosed with NHL (42). An exception to the overall increase in survival 
among HIV-infected individuals diagnosed with NHL was reported in a study examining 
survival after diagnosis with the aggressive AIDS-related forms of NHL, Burkitt’s 
lymphoma (HIV-BL) and diffuses large-cell lymphoma (HIV-DLCL) (43). This study 
suggested that while survival has markedly improved in the HAART era for individuals 
with HIV-DLCL receiving standard chemotherapy, it did not improve for individuals 
with HIV-BL undergoing standard chemotherapy (43). 
2.1.3.3 Cancer Survival by Cancer Type: Infection-related vs. Non-Infection-related  
 As certain cancers occur much more frequently among HIV-infected individuals, 
for instance, anal cancer, which is an HPV-related NADM, has an incidence rate 80-110 
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times greater among HIV-infected men who have sex with men (MSM) relative to the 
general population, it has become more common to classify cancers as infection-related 
or infection-unrelated (18). Much remains to be understood about the impact of HAART 
on infection-related NADMs. HIV-infected individuals are known to have a much higher 
risk of infection-related NADMs than does the general population (44). This greater risk 
has been attributed to the higher prevalence of certain viral co-infections (HPV, hepatitis 
B and C, HHV-8, and EBV) among HIV-infected individuals as well as the limited 
ability of HIV-infected individuals to suppress the oncogenic viral process as a result of 
their weakened immune systems (44). As HAART improves immune function, its use 
may potentially improve control of co-infections, as has already been demonstrated in the 
case of Hepatitis B clearance (44). This, however, has not been shown to be the case for 
other infections, and furthermore, is inconsistent with the rise in certain infection-related 
NADMs seen in the HAART era, such as anal cancer (44,45). Another factor to consider 
is the timing of HAART initiation, since the ability of HAART to increase CD4 cell 
count and to thereby improve immune function depends on the level of immune 
suppression (46). Patients who initiate HAART late and therefore have lower CD4 counts 
at the time of initiation face persistent inflammation and immunodeficiency and as such 
are at increased risk for developing and subsequently dying of their cancer (46).   
 A US multicenter prospective cohort study of HIV-infected individuals in clinical 
care (CNICS) examined the prognosis of individuals diagnosed with ADMs, infection-
related NADMs (where infection-related included squamous cell anal, squamous cell 
oral/pharynx, HL, liver with viral hepatitis, vaginal, vulvar, and penile), and infection-
unrelated NADMs (46). Survival was calculated from the time of cancer diagnosis until 
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death using an adjusted Cox proportional hazards regression model (46). The adjusted 
hazard of death was lower for individuals diagnosed with ADMs and infection-related 
NADMs, both relative to individuals diagnosed with infection-unrelated NADMs (46).   
2.1.4 Summary 
  While the introduction of HAART has certainly had a dramatic impact on the 
lifespan of seropositive individuals, the actual impact of HAART exposure on cancer 
mortality is less well characterized, especially since many studies classify individuals’ 
HAART exposure based on calendar year rather than the actual individual HAART 
exposure. In other words, these studies treat all individuals in the HAART era as exposed 
to HAART, even though some of them were not, which makes them studies that examine 
the effectiveness of HAART, rather than its efficacy (19,20,28). Early on, HAART was 
only being prescribed to the patients who were most ill (guidelines for HAART initiation 
fluctuated around 200 to 500 cells/μL) and in many instances it was very difficult or 
impossible to account for the factors associated with initiating HAART (47). As a result, 
in some study populations HAART users had poorer survival than non-HAART users did 
because they were sicker. This is less of a concern today since most antiretroviral drugs 
available are less toxic, have simpler regimens that make adherence more likely, and 
there is evidence of benefits of earlier HAART initiation, and so many guidelines now 
promote starting HAART treatment shortly after diagnosis, rather than basing the 
decision to initiate use on CD4 cell count (47).  Our study examined both HAART 
effectiveness and efficacy, which enabled us to assess how much or little difference there 
is between the two approaches.   
 The overarching objective of this study was to examine the effect of HAART on 
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survival following cancer diagnosis in the Multicenter AIDS Cohort Study (MACS) and 
Women’s Interagency HIV Study (WIHS) cohorts. Our first aim was to characterize and 
compare cancer survival among HIV-infected and –uninfected individuals diagnosed 
with cancer in the pre-HAART (1984-1994) and the HAART (1995-2013) eras. We 
hypothesized that survival is better among HIV-infected individuals with cancers 
diagnosed in the HAART era compared to those diagnosed in the pre-HAART era, but 
poorer than that among HIV-uninfected individuals. Next, we hypothesized that the 
survival increase in the HAART era among HIV-infected individuals was greater for 
those diagnosed with ADMs compared to those diagnosed with NADMs. Lastly, we 
hypothesized that among HIV-infected individuals, the survival increase in the HAART 
era was greater for infection-related cancers compared to non-infection related cancers. 
 The second aim of this study was to characterize and compare cancer survival in the 
HAART era by HIV status and use of HAART. We hypothesized that survival was better 
among HIV-infected individuals taking HAART at the time of cancer diagnosis than it 
was among HIV-infected individuals not taking HAART. We also hypothesized that the 
improved survival among HIV-infected individuals taking HAART was greater for 
individuals diagnosed with ADMs than it was for individuals diagnosed with NADMs. 
Finally, we hypothesized that survival was better among HIV-infected individuals taking 
HAART who were diagnosed with infection-related cancers than it was for individuals 
diagnosed with non-infection-related cancers.  
2. MATERIALS AND METHODS 
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2.1 Study Population 
 This study was nested within the Multicenter AIDS Cohort Study (MACS) and 
Women’s Interagency HIV Study (WIHS). Details of the MACS and WIHS study 
designs and populations have been described previously (48–52).  In brief, the MACS is 
an ongoing, multicenter prospective cohort study of HIV-1 infection among homosexual 
and bisexual men in the United States started in 1984 to examine the natural history of 
AIDS. Participants were initially recruited from four geographic locations (Baltimore, 
MD; Chicago, IL; Pittsburgh, PA; and Los Angeles, CA) and follow-up visits occur at 
six-month intervals. At baseline, data collection included a questionnaire to collect 
demographic information, past and current medical history, a physical exam, and 
laboratory tests. The WIHS is an ongoing, multicenter prospective cohort study of 
women who participate in high-risk behavior for HIV infection in the United States 
assembled in 1994 in response to the increased incidence of AIDS among women. 
Participants were initially recruited from six geographic sites (Bronx/Manhattan, NY; 
Brooklyn, NY; Washington DC; San Francisco/Bay Area; Los Angeles/Southern 
California/Hawaii; and Chicago, IL) and follow-up visits take place at six-month 
intervals. Data collection includes interviews (to assess medical history, drug/alcohol use, 
sexual behavior, and psychological status), a physical exam, and laboratory testing. 
2.2 Inclusion/Exclusion Criteria 
 To generate our study population, we began identifying all confirmed cancers that 
were documented in the MACS and WIHS through October 2013, and then applied the 
exclusion criteria as summarized in Figure 1. Specifically, we included only the initial 
primary cancers that were diagnosed after enrollment in the MACS or WIHS; second 
 
 15 
primaries and subsequent metastases were excluded. The date of cancer diagnosis was 
required in order to evaluate survival time, so we excluded participants with an unknown 
cancer diagnosis date. Among these participants, we included those with no more than a 
two-year gap between their last visit prior to cancer diagnosis and the diagnosis date. We 
excluded participants whose cancer was diagnosed between two study visits that were 
more than two years apart because of the increased uncertainty about their risk factor 
status at the time the cancer was diagnosed. We also excluded participants whose 
Surveillance, Epidemiology, and End Results program (SEER) Site ICD-0-3 cancer code 
was an epithelial-cell skin cancer (such as squamous cell carcinoma and basal cell 
carcinoma) because these cancers are not ascertained by the state cancer registries. 
Finally, cancers that were diagnosed within 24 hours of death were excluded because 
they represent a very different group of patients than those who were healthy enough to 
have the opportunity to receive treatment.  
2.3 Primary Outcome Measures 
 The primary outcome of interest was all-cause mortality. Participant deaths were 
ascertained through medical record abstraction, National Death Index (NDI) matching, 
and by notification of family/next of kin. While causes of death were ascertained via NDI 
matching and from death certificates, we did not incorporate cause of death information 
into this study.  
2.4 Primary Exposure Measures 
 Our primary objective was to evaluate the effect of HAART on cancer survival. 
As a means of achieving this, the primary exposures of interest were HAART era / 
HAART availability and HIV infection. We used calendar time as a metric to evaluate 
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the effectiveness of HAART.  Calendar time was stratified into the pre-HAART and 
HAART eras. Patients with a cancer diagnosis prior to January 1, 1995 were classified as 
pre-HAART era patients, and patients with a cancer diagnosis after January 1, 1995 were 
classified as HAART era patients. HIV seropositivity was determined using blood drawn 
at each biannual visit. For MACS participants, enzyme-linked immunoadsorbent assays 
(EIA) were used to detect HIV seropositvity, and Western blot assays were used for 
confirmation (48). For WIHS participants, ultrafrozen sera samples were tested using the 
NASBA commercial assay to quantify HIV RNA viral load (49). HAART use in both 
cohorts in this study was defined based on the 2008 DHHS/Kaiser definitions. As of 
November 2008, HAART use in the MACS was defined as:  
“…three or more antiretroviral drugs consisting of one or more PIs or one NNRTI 
or the NRTIs - Abacavir or Tenofovir, or an integrase or an entry inhibitor. The 
percentages are based on total HIV+ person-visits with available therapy data 
from July 1995 to March 2010. …[s]pecific combinations subject to the following 
restriction criteria include (a) two or more NRTIs with one NNRTI or with one or 
more PIs (87%); (b)one NNRTI co-administered with one ritonavir (RTV) 
boosted PI with or without NRTI (7%); (c) an abacavir or tenofovir containing 
regimen of three or more NRTIs in the absence of both PIs and NNRTIs (4%), (d) 
two or more RTV boosted PIs with or without other ARTs (1%); and (e) an 
integrase or entry inhibitor with a combination of two other antiretroviral drugs 
(1%) except for two unboosted PIs. Regimens containing the following 
combinations are not considered HAART: two or more NNRTIs, an NNRTI 
without a (RTV) boosted PI, unboosted atazanavir with TDF, boosted nelfinavir 
(NFV), and two NRTI combinations - zidovudine (AZT) + stavudine (d4T) or 
emtricitabine (FTC) + lamivudine (3TC). Enfuvirtide (T-20) or Maraviroc 
(Selzentry) or Ralegravir (Isenress) with two or more antiretroviral drugs except 
for all exclusions listed above were considered HAART. All other ART regimens 
were classified as combination therapy that did not meet the HAART definition” 
(53).  
After April 2008, HAART use in the WIHS was defined as:  
 
“…the reported use of three or more antiretroviral medications, one of 
which has to be a PI, an NNRTI, one of the NRTIs abacavir or tenofovir, 
an integrase inhibitor (e.g., raltegravir), or an entry inhibitor (e.g., 
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Maraviroc or enfuvirtide)” (54).  
 
2.5 Statistical Methods  
 For this analysis, since pre-HAART era data in the WIHS are limited, we utilized 
MACS data to compare cancer survival during the pre-HAART and HAART eras (Aim 
1), and then used data from both WIHS and MACS accrued in the HAART era to 
determine whether cancer survival differs by HIV status or among HIV-infected 
participants who were taking HAART versus not taking HAART at the time of cancer 
diagnosis (Aim 2). For MACS participants who were diagnosed in the pre-HAART era, 
survival was censored at January 1, 1995 to prevent potential later HAART use from 
biasing the survival estimates of those whose cancers were diagnosed in the pre-HAART 
era. Additionally, the few cancers diagnosed among WIHS participants during the pre-
HAART era were excluded. To account for different mechanisms of cancer development, 
we stratified cancers in two ways: (1) ADMs and non-ADMs, and (2) cancers that have 
been linked to a viral infection, and cancers that have not been linked to a viral infection. 
For this study, we classified anal, liver, stomach, vaginal, vulvar, oral, HL, KS (in HIV-
uninfected individuals), NHL (in HIV-uninfected individuals), and cervical cancer (in 
HIV-uninfected individuals) as infection-related NADMs. Although some investigators 
have examined the hypothesis that prostate cancer has a viral etiology, we chose not to 
classify prostate cancer as an infection-related cancer because, unlike the other cancers 
we classified as infection-related NADMs, no one infectious agent has been definitively 
linked to prostate cancer. Cancer confirmation was based on multiple sources of 
information including biopsy, autopsy, imaging, medical records, and/or matching to 




 Demographic and clinical characteristics were assessed at the time of the visit prior to 
cancer diagnosis (Table 1). These cofactors included: age (<30 years, 30-39 years, 40-49 
years, 50-59 years, ≥ 60 years), race (White, Black, and Other), sex, body mass index 
(categorized according to CDC guidelines as: underweight (<18.5 kg/m2), normal (18.5-
24.9 kg/m2), and overweight/obese (>25.0 kg/m2)), intravenous drug use (current/non-
current), smoking history (current/non-current). HIV-related cofactors were also assessed 
at the visit prior to cancer diagnosis. These cofactors included HIV viral load (>10,000 
cp/ml as compared to <10,000 cp/ml), nadir CD4 cell count (<200 cells/μl as compared to 
>200 cells/μl), and prior AIDS diagnosis. We implemented a last observation carried 
forward imputation method for participants who had no more than a two-year gap 
between their last visit and the date of cancer diagnosis but were missing a value of a 
covariate at the visit prior to cancer diagnosis. This strategy allowed for values up to two 
years prior to the date of cancer diagnoses to be substituted for the missing values. 
Afterward, we conducted a complete case analysis.  
 We evaluated 5-year survival following cancer diagnosis using Kaplan-Meier curves 
and adjusted Cox proportional hazards models where survival time was calculated from 
the date of cancer diagnosis to the earliest of death or the last follow-up (censoring) date. 
We chose to examine 5-year survival instead of overall survival since it is a common 
prognostic measure used in cancer statistics (such as those reported by SEER), and 
because there of concern that beyond the 5-years survival trends may be driven by small 
sample size in certain groups (Figure 2) (5).  
 We assessed the proportional hazard assumption visually using complementary log-
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log regression plots, and used the global log rank test to compare survival curves. When 
there was concern that the proportional hazards assumption was violated, we evaluated 
the extent of the violation by fitting unadjusted Cox time-dependent Relative Hazards 
regression model of the main effects and an interaction term between the main effects. If 
the interaction between the main effects was statistically significant based on the Wald 
test, we ran additional univariable Cox time-dependent Relative Hazards regression 
models that were stratified by the other main effect. Since in all the models where the 
proportional hazards assumption appeared to be violated, the issue could be isolated to a 
single group being compared, the final adjusted Cox time-dependent Relative Hazards 
regression model included an interaction with time for that particular group to address the 
issue of non-proportionality.  
 For each hypothesis, we fit univariable and multivariable Cox proportional hazard 
models compared them using the Akaike information criterion (AIC). The multivariable 
Cox models were adjusted for the following time-fixed cofactors assessed at the last visit 
prior to cancer diagnosis: age, race, intravenous drug use (IDU), smoking history, 
sex/cohort, body mass index (BMI), HIV viral load, nadir CD4 cell count, and prior 
AIDS diagnosis. We explored several different strategies (adjustment for sex, running 
separate models stratified by sex, and allowing for the baseline hazard functions to differ 
by sex) to account for substantial differences between the cohorts with regards to several 
covariates (ex. age, BMI, race). As these strategies yielded similar results, and based on a 
comparison of the AIC values, the models that allowed for differing baseline hazards 
appeared to be preferable, these models were presented as the final models.   
 All reported P values are two-sided and were considered statistically significant if p ≤ 
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0.05. All data analyses were conducted using Stata, version 13.0 (Stata Corporation, 
College Station, Texas, USA).
3. RESULTS 
 21 
The baseline demographic, clinical, and laboratory characteristics of the study 
population are described in Table 1. The 911 participants who met the inclusion criteria 
described in Section 2.2 contributed a total of 2697.2 person-years of follow-up. There 
were a few notable differences between WIHS and MACS participants. The WIHS 
participants were slightly older than the MACS participants at the time of cancer 
diagnosis (median age (IQR): 48.1 (41.1 – 53.8) years, 41.2 (35.1 – 50.1) years, 
respectively, p < 0.001). The WIHS participants more frequently identified as Black, non-
Hispanic (60.0%), while the MACS participants more frequently identified as White, 
non-Hispanic (84.5%) (p < 0.001). The WIHS participants also had higher BMIs than did 
the MACS participants (median BMI (IQR): 26.6 (22.0 – 32.4) kg/m2 and 23.1 (21.4 – 
25.3) kg/m2, respectively, p < 0.001). Of the WIHS participants, 61% reported being 
current smokers at the visit prior to cancer diagnosis, as compared to about 27% of the 
MACS participants (p < 0.001). Among the smokers, the MACS participants had greater 
cumulative pack-years than did the WIHS participants (median cumulative pack-years 
(IQR): 24.0 (10.3 – 38.8) versus 14.9 (9.0 – 28.4), however, this difference was not 
statistically significant (p = 0.10). HIV-infection was more common among the WIHS 
participants than among the MACS participants (85.8% relative to 80.8%), and the WIHS 
participants were also more likely to have AIDS (51.0% relative to 17.7%, p < 0.001). 
Viral load was significantly higher among the MACS participants as compared to the 
WIHS participants (median viral load (IQR): 172,341 cp/ml (71,256 – 361,153 cp/ml) 
versus 23,000 cp/ml (4,300 – 110,000 cp/ml)), p < 0.001. Correspondingly, nadir CD4 
cell count was also higher in the WIHS participants than did the MACS participants 
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(median CD4 cell count (IQR): 173 cells/μl (84 – 287 cells/μl) as compared to 106 
cells/μl (42 – 247 cells/μl), p < 0.001).  
The majority of incident cancers observed in the study population were ADMs 
(55.8%), followed by non-infection related NADMs (32.2%), and lastly infection-related 
ADMs (9.7%) (Table 2). As the MACS data included follow-up during both pre-HAART 
and HAART eras, and the WIHS follow-up was strictly from the HAART era, the 
majority of the ADMs were observed in MACS participants (91.5%). The three most 
common NADMs observed in the study population were: prostate cancer (14.2%), lung 
cancer (13.6%), and breast cancer (10.8%).  
Aim 1: Hypothesis 1 
We compared 5-year cancer survival during the pre-HAART and HAART eras 
among the 701 MACS participants who met the study inclusion criteria. During the 
1460.3 person-years of follow-up the men accrued, 437 participants (62.3%) died within 
5 years, yielding a 5-year mortality rate of 29.9 deaths / 100 person-years (95% CI: 27.2 
– 32.9 deaths / 100 person-years). The 5-year mortality rates following cancer diagnosis 
by HIV status and era were: 4.7 deaths/100 person-years (95% CI: 2.6 – 7.9) for HIV(-) 
participants diagnosed in the HAART era, 16.3 deaths/100 person-years (95% CI: 9.8 – 
25.4) for HIV(-) participants diagnosed in the pre-HAART era HIV(-), 12.2 deaths/100 
person-years (95% CI: 9.2 – 15.9) for HIV(+) participants diagnosed in the HAART era, 
58.6 deaths/100 person-years (95% CI: 52.6 – 65.1) for HIV(+) participants diagnosed in 
the pre-HAART era.  
The Kaplan-Meier curves for participants by HIV status and era showed that the 
5-year cumulative probability of survival following a cancer diagnosis was lowest among 
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HIV(+) participants diagnosed with cancer the in pre-HAART era (0.06, 95% CI: 0.04 – 
0.10) and highest among HIV(-) participants diagnosed in the HAART era (0.81, 95% CI: 
0.70 – 0.88) (Figure 3). The global log rank test indicated that the survival curves were 
statistically significantly different (p < 0.001). The curves for HIV(-) participants in the 
pre-HAART era and HIV(+) participants in the HAART era were roughly equivalent. 
Visual inspection of the complementary log-log regression plot comparing the four 
groups indicated that the proportional hazards assumption was violated. To determine the 
extent of the violation of the proportional hazards assumption, we fit univariable Cox 
time-dependent Relative Hazards regression models of the main effects (HIV status and 
era). As only the interaction between era and time was statistically significant based on 
the Wald test (p = 0.001), additional univariable Cox time-dependent Relative Hazards 
regression models of era were run separately for HIV(+) and HIV(-) participants. The 
interaction between era and time was only significant for the HIV(+) participants (p < 
0.001), and so the final multivariable Cox time-dependent Relative Hazards regression 
model included an interaction with time for HIV(+) participants in the pre-HAART era 
(Table 4).  
In the final adjusted model examining the cancer survival by HIV status and 
HAART era, the interaction term between time and HIV(+) participants who received a 
cancer diagnosis in the pre-HAART era was statistically significant, which indicated that 
the relative hazard increased with time (adjusted hazard ratio, 1.70 per year; 95% CI, 1.39 
– 2.07). Based on this model, the adjusted relative hazard 2 years after cancer diagnosis 
increased to 2.81 (95% CI, 1.35 – 5.83) and then to 8.08 (95% CI, 3.36 – 19.42) after 4 
years. Participants who were diagnosed after age 60 years had a lower hazard of death as 
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compared to participants diagnosed before age 30 years. Participants who were 
overweight or obese at the last visit prior to cancer diagnosis had a lower hazard of death 
relative to normal weight participants, while those with a prior AIDS diagnosis had a 
greater hazard of death relative those without an AIDS diagnosis. Among HIV(+) 
participants, viral load > 10,000 cp/ml and nadir CD4 cell count < 200 cells/μl were each 
significantly associated with a higher hazard of death.   
Aim 1: Hypothesis 2  
To explore the impact of the introduction of HAART on cancer survival further, 
we next examined cancer survival among individuals diagnosed with ADMs and 
NADMs. In the 5-year analysis, 556 MACS participants who were HIV(+) at the visit 
prior to cancer diagnosis, met the inclusion/exclusion criteria described above, and did 
not have a “Miscellaneous” SEER code contributed a total 1,021.6 person-years of 
follow-up. Among these participants, 397 participants (71.4%) participants died during 
follow-up, yielding a 5-year mortality rate of 38.9 deaths/100 person-years (95% CI: 35.1 
– 42.9).  
We first explored differences in cancer survival by cancer type (ADM vs. 
NADM) and era. The 5-year mortality rates by era and cancer type were: 6.5 deaths/100 
person-years (95% CI: 3.7 – 10.6) among participants diagnosed with NADMs in the 
HAART Era, 18.5 deaths/100 person-years (95% CI: 12.9 – 25.7) among participants 
diagnosed with ADMs in the HAART era, 27.1 deaths/100 person-years (95% CI: 13.5 – 
48.5) among participants diagnosed with NADMs in the pre-HAART era, and 61.4 
deaths/100 person-years (95% CI: 55.0 – 68.4) among participants diagnosed with ADMs 
in the pre-HAART era. The Kaplan-Meier curves comparing survival of participants 
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diagnosed with an NADM in the HAART Era, participants diagnosed with an ADM in 
the HAART era, participants diagnosed with an NADM in the pre-HAART era, and 
participants diagnosed with an ADM in the pre-HAART era suggested that the 5-year 
hazard of death following a cancer diagnosis was highest among participants diagnosed 
with an ADM in the pre-HAART era and lowest among participants diagnosed with an 
NADM in the HAART era (Figure 4). The global log rank test indicated that the curves 
were significantly different (p < 0.001) The curves of participants diagnosed with an 
ADM in the HAART era and participants diagnosed with an NADM in the pre-HAART 
were fairly similar, with participants diagnosed with ADMs in the HAART era appearing 
to have slightly improved survival after one year of follow-up. Visual inspection of the 
complementary log-log regression plot comparing the four groups indicated that the 
proportional hazards assumption was violated. The extent of the violation of the 
proportional hazards assumption was assessed as described previously. Based on the 
results, the final adjusted Cox time-dependent Relative Hazards regression model 
included an interaction with time for participants diagnosed with ADMs in the pre-
HAART era (Table 6).  
In this final adjusted model, the interaction term between time and HIV(+) 
participants who received a cancer diagnosis in the pre-HAART era was statistically 
significant, which indicates that the relative hazard increased over time (adjusted HR 
increase per year, 1.74; 95% CI: 1.39 – 2.19). Based on this model, the adjusted relative 
hazard 2 years after cancer diagnosis increased to 7.68 (95% CI, 3.89 – 15.18) and then to 
23.2 (95% CI, 9.41 – 57.3) after 4 years. As the Kaplan-Meier curves indicated, 
individuals diagnosed with ADMs in the pre-HAART era had the greatest hazard of 
 
 26 
death, followed by participants diagnosed with NADMs in the pre-HAART era (adjusted 
HR: 4.91; 95% CI: 2.12 – 11.39), and then participants diagnosed with ADMs in the 
HAART era (adjusted HR: 2.12; 95% CI: 1.08 – 4.50). Participants who were overweight 
or obese at the visit prior to cancer diagnosis had a lower hazard of death relative to 
normal weight participants. Having a prior AIDS diagnosis, being a current smoker, 
having a viral load > 10,000 cp/ml, and having a nadir CD4 cell count < 200 cells/μl were 
each associated with a greater hazard of death.  
Aim 1: Hypothesis 3  
Next, we explored cancer survival by cancer type (infection-related or non-
infection related) and era using the same 556 MACS participants described in Aim 1: 
Hypothesis 2. The 5-year mortality rates by era and cancer type were as follows: 4.6 
deaths/100 person-years (95% CI: 1.8 – 9.4) among participants diagnosed with non-
infection-related cancers in the HAART era, 15.6 deaths/100 person-years (95% CI: 11.3 
– 20.9) among participants diagnosed with infection-related cancers in the HAART era, 
37.1 deaths/100 person-years (95% CI: 17.0 – 70.4) among participants diagnosed with 
non-infection-related cancers in the pre-HAART era, and 60.0 deaths/100 person-years 
(95% CI: 53.8 – 66.8) among participants diagnosed with infection-related cancers in the 
pre-HAART era.  
The Kaplan-Meier curves comparing survival of participants cancer type 
(infection-related or non-infection related) and era indicated that the 5-year hazard of 
death following a cancer diagnosis was highest among participants diagnosed with 
infection-related cancers in the pre-HAART era and lowest among participants diagnosed 
with non-infection-related cancers in the HAART era (Figure 5). During the first 18 
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months of follow-up, the curves for participants diagnosed with infection-related cancers 
in the HAART era, participants diagnosed with non-infection related cancers in the pre-
HAART era, and participants diagnosed infection-related cancers in the pre-HAART era 
intersected several times, but thereafter, survival was better among participants diagnosed 
with infection-related cancer in the HAART era, followed by participants diagnosed with 
non-infection related cancers in the pre-HAART era, and then participants diagnosed 
with infection-related cancers in the pre-HAART era. The global log rank test indicated 
that the survival curves were statistically different (p < 0.001). Visual inspection of the 
complementary log-log regression plot comparing the four indicated that the proportional 
hazards assumption was violated. The extent of the violation of the proportional hazards 
assumption was assessed as described previously. Based on the results, the final adjusted 
Cox time-dependent Relative Hazards regression model included an interaction with time 
for participants diagnosed with infection-related cancers in the pre-HAART era (Table 7).  
In this final adjusted model, individuals diagnosed with non-infection-related 
cancers in the pre-HAART era had a 6.56 times greater hazard of death relative to those 
diagnosed with non-infection related cancers in the HAART era (95% CI: 2.33 – 18.48). 
Once the interaction term between time and participants diagnosed with infection-related 
cancers who received a cancer diagnosis in the pre-HAART era was included in the 
model, the effect for participants diagnosed with infection-related cancers in the pre-
HAART era was no longer significant (p = 0.06), however, the interaction term was. This 
indicated that the relative hazard increases in a log-linear fashion (adjusted HR increase 
per year, 1.72; 95% CI: 1.36 – 2.18). Based on this model, the adjusted relative hazard 2 
years after cancer diagnosis increased to 7.33 (95% CI: 3.02 – 17.84) and then to 21.71 
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(95% CI: 7.38 – 63.82) after 4 years. Participants who were overweight or obese at the 
last visit prior to cancer diagnosis had a lower hazard of death relative to normal weight 
participants. Being a current smoker, having a prior AIDS diagnosis, and having a nadir 
CD4 cell count < 200 cells/μl, were each independently associated with significantly 
greater hazards of death. 
Aim 2: Hypothesis 1  
In Aim 2, we explored the effect of HAART on cancer survival more directly by 
comparing survival between those taking versus not taking HAART immediately prior to 
cancer diagnosis. Subsequent analyses were restricted to the HAART era and included 
participants from both MACS and WIHS cohorts. In the 5-year survival analysis, the 439 
participants who met the inclusion/exclusion criteria described in Section 2.2 contributed 
a total of 1257.2 person years of follow-up. Among these participants, 229 participants 
(52.2%) died during follow-up, and the 5-year mortality rate was 18.2 deaths/100 person-
years (95% CI: 15.9 – 20.7). The cohort-specific 5-year mortality rates were: 31.4 
deaths/100 person-years (95% CI: 26.7 – 36.7) for WIHS and 9.2 deaths/100 person-
years (95% CI: 7.2 – 11.7). The 5-year mortality rates following cancer diagnosis by HIV 
status and HAART use were as follows: 8.9 deaths/100 person-years (95% CI: 6.2 – 
12.4) for HIV(-) participants, 19.7 deaths/100 person-years (95% CI: 16.1 – 24.0) for 
HIV(+) participants using HAART at the visit prior to cancer diagnosis, and 25.8 
deaths/100 person-years (95% CI: 20.9 – 31.5) for HIV(+) participants not using HAART 
at the visit prior to cancer diagnosis.  
The Kaplan-Meier curves comparing survival of participants by HIV status and 
HAART use suggested that the 5-year hazard of death following a cancer diagnosis was 
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highest among HIV(+) participants not using HAART and lowest among HIV(-) 
participant (Figure 6). The global log rank test results indicated that the survival curves 
were statistically different (p < 0.001). Visual inspection of the complementary log-log 
regression plot comparing the three indicated that the proportional hazards assumption 
was likely not violated. To confirm this, we assessed the potential for violation of the 
proportional hazards assumption as described previously. None of the stratified results 
indicated that there was a group whose description of the relative hazard would be 
improved by including an interaction with time, suggesting that the assumption was not 
violated. 
The final adjusted model allowed for differing baseline hazards by cohort to 
account for aforementioned notable differences between the two cohorts (Table 9). In this 
model, HIV(+) participants using HAART had a lower hazard of death relative to HIV(-) 
participants, and HIV(+) not using HAART had a greater hazard of death relative to 
HIV(-) participants however, neither of these were statistically significant (adjusted HR: 
0.92; 95% CI: 0.57 – 1.48; adjusted HR: 1.26; 95% CI: 0.78 – 2.05, respectively). HIV(+) 
participants not using HAART had a statically significant greater hazard of death than did 
those using HAART (adjusted HR: 1.38; p = 0.05).  Individuals who were current 
smokers had a greater hazard of death relative to non-current smokers. Additionally, 
having a prior AIDS diagnosis and having a nadir CD4 cell count < 200 cells/μl were 
each associated with a greater hazard of death. 
Aim 2: Hypothesis 2 
Next, we explored cancer survival by cancer type (NADM or ADM, infection-
related or non-infection related) and HAART use among HIV(+) individuals whose 
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cancer was not classified as “Miscellaneous.” In the five-year survival analysis, the 310 
participants who met the inclusion/exclusion criteria described in Section 2.2 contributed 
a total of 847.0 person years of follow-up. Among these participants, 184 participants 
(59.3%) died during follow-up, and the 5-year mortality rate was 21.7 deaths/100 person-
years (95% CI: 18.7 – 25.1). The 5-year mortality rates following cancer diagnosis by 
cancer type (NADM or ADM) and HAART use were: 19.1 deaths/100 person-years 
(95% CI: 15.0 – 23.9) for individuals diagnosed with NADMs using HAART, 18.6 
deaths/100 person-years (95% CI: 11.0 – 29.4) for individuals diagnosed with ADMs and 
using HAART, 24.8 deaths/100 person-years (95% CI: 17.9 – 33.5) for individuals 
diagnosed with NADMs not using HAART, and 26.0 deaths/100 person-years (95% CI: 
19.3 – 34.4) for individuals diagnosed with ADMs not using HAART. 
The Kaplan-Meier curves comparing survival of participants by cancer type and 
HAART use indicated that the 5-year hazard of death following a cancer diagnosis was 
highest among individuals diagnosed with ADMs not using HAART and lowest among 
individuals diagnosed with NADMs using HAART (Figure 7), however, each of the 
survival curves intersected another at some point during the 5 year follow-up. The results 
of the global log rank test indicated that the survival curves were not different (p = 0.24). 
Visual inspection of the complementary log-log regression plot comparing the four 
groups suggested that the proportional hazards assumption was not violated.  
The final adjusted model allowed for differing baseline hazards by cohort to 
account for aforementioned differences between the cohorts (Table 11). In this model, 
HIV(+) individuals using HAART had a lower hazard of death as compared to HIV(+) 
individuals not using HAART, and this effect was statistically significant (adjusted HR: 
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0.68; 95% CI: 0.48 – 0.96). An interaction term between cancer type and HAART use 
was included in one of the earlier models to test for effect modification, and as it was not 
significant (p = 0.22), it was not included in the final model. Individuals who identified 
as Black, non-Hispanic had a greater hazard of death as compared to individuals who 
identified as White, non-Hispanic. Furthermore, having a prior AIDS diagnosis and a 
nadir CD4 cell count < 200 cells/μl were also independently associated with an elevated 
hazard of death. 
Aim 2: Hypothesis 3  
Lastly, we evaluated cancer survival by cancer type (infection-related or non-
infection-related) and HAART use using the same 310 participants described in Aim 2: 
Hypothesis 2. The 5-year mortality rates following cancer diagnosis by cancer type and 
HAART use were: 16.2 deaths/100 person-years (95% CI: 11.3 – 22.4) for individuals 
diagnosed with infection-related cancers using HAART, 21.3 deaths/100 person-years 
(95% CI: 16.2 – 27.7) for individuals diagnosed with non-infection-related cancers using 
HAART, 22.6 deaths/100 person-years (95% CI: 15.6 – 31.6) for individuals diagnosed 
with non-infection-related cancers not using HAART, and 27.5 deaths/100 person-years 
(95% CI: 20.9 – 35.7) for individuals diagnosed with infection-related cancers not using 
HAART. 
The Kaplan-Meier curves comparing survival of participants by cancer type and 
HAART use indicated that the 5-year hazard of death following a cancer diagnosis was 
highest among individuals diagnosed with infection-related-cancers not using HAART 
and lowest among individuals diagnosed with infection-related cancers using HAART 
(Figure 8), however, the survival curves of participants other than those diagnosed with 
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infection-related cancers not using HAART were similar. The results of global the log 
rank test indicated that the survival curves for the four groups were not different (p = 
0.10). Visual inspection of the complementary log-log regression plot comparing the four 
groups suggested that the proportional hazards assumption was not violated.  
The final adjusted model allowed for differing baseline hazards by cohort to 
account for aforementioned differences between the two cohorts (Table 12). Based on 
this model, participants diagnosed with non-infection-related cancers using HAART at 
the visit prior to cancer diagnosis had 1.07 times the hazard of death as compared to those 
not using HAART, however, this elevated hazard was not significant (95% CI: 0.67 – 
1.72). Individuals diagnosed with infection-related cancers using HAART had a 
statistically significant lower hazard of death as compared to those not using HAART 
(adjusted HR: 0.36, 95% CI: 0.19 – 0.69) (Table 13). This indicated that HAART 
improved survival for participants diagnosed with infection-related cancers but had little 
or no effect on survival for individuals diagnosed with non-infection-related cancers. The 
interaction term between the HAART use and infection-related cancer was statistically 
significant, which indicated that the effect of having an infection-related cancer was 
modified by HAART use (p = 0.002). Therefore, according to this model, among 
HAART non-users, HIV(+) participants diagnosed with infection-related cancers had 
1.98 times the hazard of death as compared to HIV(+) participants diagnosed with non-
infection-related cancers (95% CI: 1.18 – 3.32). Among HAART users, HIV(+) 
participants diagnosed with infection-related cancers had 0.71 times the hazard of death 
as compared to HIV(+) participants diagnosed with non-infection related cancers (95% 
CI: 0.44 – 1.13). Participants who identified as Black, non-Hispanic had a greater hazard 
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of death relative to individuals who identified as White, non-Hispanic. Having a prior 
AIDS diagnosis and a nadir CD4 cell count < 200 cells/μl were each independently 
associated with a greater hazard of death. 
4. DISCUSSION 
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 Since the start of the AIDS pandemic, cancer has been an important cause of 
mortality among individuals living with HIV. This study examines the impact of HAART 
in two ways – by comparing mortality in the pre-HAART and HAART eras and also by 
comparing mortality during the HAART era between those where taking versus not 
taking HAART at the time cancer was diagnosed. Our finding of the improved survival 
among HIV-infected individuals with cancers diagnosed in the HAART era compared to 
those diagnosed in the pre-HAART era is consistent with previous studies (34,35). 
During the HAART era, we found that cancer survival was statistically indistinguishable 
between HIV-infected and HIV-uninfected individuals nor did survival differ among 
HIV-infected individuals diagnosed with ADMs as compared to those diagnosed with 
NADMs. Interestingly, we observed that cancer survival differed significantly by 
HAART use among those diagnosed with infection-related cancers, but not among those 
diagnosed with non-infection-related cancers. Taken together, the results from this study 
demonstrate the important role of HAART in cancer survival for individuals diagnosed 
with infection-related cancers and support the need for future research into how the 
impact of HAART varies by cancer type among individuals with infection-related 
cancers. 
  In our analysis comparing cancer survival among all study participants diagnosed 
with cancer in the pre-HAART and the HAART eras, we found that HIV-infected 
individuals with cancers diagnosed in the HAART era had improved survival compared 
to those diagnosed in the pre-HAART era. This finding is consistent with those reported 
in previous studies (34,35). Among HIV-infected individuals, we noted that participants 
diagnosed with NADMs in the pre-HAART era had a greater hazard of death as 
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compared to participants diagnosed with NADMs in the HAART era, and that 
participants diagnosed with ADMs in the HAART era had a greater hazard of death than 
did individuals diagnosed with NADMs in the HAART era. We also examined survival 
in the pre-HAART and HAART eras among HIV-infected individuals for infection-
related versus non-infection-related cancers, and found that the cancer survival increase 
following the introduction of HAART was greater for participants diagnosed with 
infection-related cancers. Participants with infection-related cancers diagnosed in the pre-
HAART era had an elevated hazard of death at baseline that increased by a factor of 1.72 
per year following cancer diagnosis, relative to individuals diagnosed in the HAART era. 
In comparison, participants diagnosed with non-infection-related cancers in the pre-
HAART era had 6.56 times the hazard of death relative to individuals diagnosed in the 
HAART era. Although, the greater improvement in survival among individuals diagnosed 
with infection-related cancers was anticipated given that HAART improves immune 
function, previous studies have demonstrated that the relationship between HAART and 
HIV infection is complicated and the timing of HAART initiation has been shown to be 
instrumental (44–46).  
  Comparing survival by HIV status in the HAART era in Aim 1, without 
accounting for HAART use, we noted that survival was comparable among HIV-infected 
and HIV-infected participants. When included HAART use information in Aim 2, we 
again saw no statistically significant difference in the hazard of death of HIV-uninfected 
as compared to HIV-infected individuals both using and not using HAART. Previous 
studies, on the other hand, have reported that, perhaps with the exception of NHL, there 
remains a gap in survival between HIV-infected and HIV-uninfected individuals in the 
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HAART era (36,38). The main contributor to improved survival among HIV-infected 
individuals is undoubtedly HAART use, as mortality was higher among HIV-infected 
participants not using HAART in the HAART era relative to those using HAART. 
Together with our finding that survival among HIV-uninfected individuals did not differ 
significantly in the two eras, this suggests that the improved survival for HIV-infected 
individuals in the HAART era is not primarily due to advances in cancer treatment over 
time or other secular trends not specific to HIV-infected individuals. Rather, it is most 
likely to be attributed to HAART use as well as possibly to improvements in clinical 
surveillance improved for HIV-infected individuals, particularly those with risk factors 
for cancer, as the lifespan of individuals living with HIV increased and they began 
developing aging-related conditions.  
Examining the impact of HAART use on survival in the HAART era, we 
observed that there was no difference in survival by cancer type (ADM vs. NADM), but 
that individuals taking HAART at the visit prior to cancer diagnosis had a significantly 
lower hazard of death than those not taking HAART. This result is consistent with 
several previous studies that reported that survival does not differ for HIV-infected 
individuals diagnosed with ADMs as compared to those diagnosed with NADMs (34,40). 
One study, however, reported that HAART is less effective for individuals diagnosed 
with NADMs than for individuals diagnosed with ADMs (41).  
Interestingly, when we examined the impact of HAART on survival by cancer 
type (infection-related versus not infection-related), we found that HAART only appears 
to have an impact for individuals diagnosed with infection-related cancers. Specifically, 
the interaction term between infection-related cancer and HAART use was highly 
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significant, but the effect of HAART for those with non-infection-related cancers was not 
significant. Stratified by HAART use, non-HAART using HIV(+) participants diagnosed 
with infection-related cancers a greater the hazard of death as compared to HIV(+) 
participants diagnosed with non-infection-related cancers. Among HAART users, 
however, HIV(+) participants diagnosed with infection-related cancers had decreased 
hazard of death as compared to HIV(+) participants diagnosed with non-infection related 
cancers. Since HAART improves immune function, it was anticipated that it would also 
improve control of co-infections, and thereby lead to improved survival among co-
infected individuals. Our results are consistent with those from a multicenter prospective 
study, which reported that individuals diagnosed with ADMs and infection-related 
NADMs, both had a lower hazard of death relative to individuals diagnosed with 
infection-unrelated NADMs (46).    
This study has important strengths and limitations. A key strength of this study 
was the recruitment of HIV-uninfected participants in addition to HIV-infected 
participants, which provided an internal comparison group. The presence of an internal 
comparison group enabled us to obtain more accurate estimates of the hazard of death 
than could be calculated using an external comparison group (such as that from the 
general population). Another important strength is that we possessed both pre-HAART 
era and HAART era data. This allowed us to compare survival before and after the 
introduction of HAART and to examine HAART use in two ways – using HAART era as 
a proxy for HAART use and using actual HAART use data for individuals diagnosed in 
the HAART era.    
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A number of limitations should be considered. We could not include cancer 
stage/grade data in this analysis since it was limited, however, this data is an important 
predictor of hazard of death, and our hazard ratio estimates would be improved by its 
inclusion. The estimates could also be improved by the inclusion of income (or another 
predictor of socioeconomic status such as employment) and education as covariates. 
Additionally, we did not examine cause of death in our analysis, and as such did not 
investigate the possibility that survival differences could be due to differential cancer-
specific mortality rates. Another limitation is that this analysis included time-fixed 
covariates assessed at the visit prior to cancer diagnosis, and as such did not allow for 
individuals to switch exposure groups during the course of the analysis. Finally, we did 
not account for lack of adherence to HAART treatment. Future analyses will be 
performed to extend the current analysis by addressing these limitations where possible.  
In conclusion, although HAART has dramatically extended the lifespan and 
improved the quality of life of individuals living with HIV, it has also resulted in an 
increase in aging-related morbidities among those infected with HIV. Certain NADMs in 
the HIV-infected population are on the rise, and there is a need to work towards 
improving cancer prevention and treatment in this population (23,24). The findings of 
this study demonstrate that HAART use is associated with a lower hazard of death for 
individuals diagnosed with infection-related cancers. Future research should extend the 
current study by examining the impact of HAART on survival among those diagnosed 
with infection-related cancers varies by cancer type to determine whether the beneficial 











Total ( n = 911)  WIHS ( n = 210) MACS ( n = 701)   p-valuea 
Median (IQR) No. % Median (IQR) No. % Median (IQR) No.  % 
Age (in years) 42.5 (36.2 – 51.5)  48.1 (41.1 – 53.8)  41.2 (35.1 – 50.1)  
   < 30 49 5.4 5 2.4 44 6.3  
   30 - 39  302 33.2 39 18.6 263 37.5  
   40 - 49 301 33.0 84 40.0 217 31.0  
   50 - 59 178 19.5 65 31.0 113 16.1  
   60 + 81 8.9 17 8.1 64 9.1 <0.001 
Race        
   White, non-Hispanic 627 68.8 35 16.7 592 84.5  
   Black, non-Hispanic 189 20.7 126 60.0 63 9.0  
   Other 95 10.4 49 23.3 46 6.6 <0.001 
IDU        
   Never 724 79.5 121 57.6 603 86.0  
   Former 168 18.4 82 39.1 86 12.3 
   Current 19 2.1 7 3.3 12 1.7 <0.001 
BMI  23.5 (21.4 – 26.3)   26.6 (22.0 – 32.4)   23.1 (21.4 – 25.3)    
   Normal (18.5 – 24.9) 552 60.6 68 32.4 484 69.0  
   Underweight ( < 18.5) 39 4.3 19 9.0 20 2.9  
   Overweight (25.0 – 29.9) 206 22.6 48 22.9 158 22.5  
   Obese (30 +) 114 12.5 75 35.7 39 5.6 <0.001 
Smoking History        
   Never 255 28.0 29 13.8 226 32.2  
   Former 339 37.2 53 25.2 286 40.8  
   Current 317 34.8 128 61.0 189 27.0 <0.001 
Abbreviations: IDU, Intravenous Drug User; BMI, Body Mass Index (Weight (kg) / Height (m2)) 









Total ( n = 911)  WIHS ( n = 210) MACS ( n = 701)   p-valuea 
Median (IQR) No. % Median (IQR) No. % Median (IQR) No.  % 
Year of Cancer Diagnosis 
   1984 - 1994 472 51.8 N/A 0.0 472 67.3 
   1995 - 2013 439 48.2 210 100.0 229 32.7 <0.001 
HIV/AIDS Status        
   HIV - 165 18.1 30 14.3 135 19.3  
   HIV + / AIDS - 515 56.5 73 34.8 442 63.1  
   HIV + / AIDS +  231 25.4 107 51.0 124 17.7 <0.001 
HIV Viral Load (among HIV+) 141,988 (43,000 – 330,000) 23,000 (4,300 – 110,000) 172,341 (71,256 – 361,153) 
   Undetectable ( < 400 cp/ml) 140 18.8 71 39.4 69 12.2 
   < 10,000 cp/ml 77 10.3 39 21.7 38 6.7 
   > 10,000 cp/ml 529 70.9 70 38.9 459 81.1 <0.001 
Nadir CD4 Cell Count (among HIV+) 123 (45 – 262) 173 (84 – 287) 106 (42 – 247) 
   > 200 cells/µl  251 33.7 80 44.4 171 30.2 
   < 200 cells/µl  495 66.4 100 55.6 395 69.8 <0.001 
HAART Experienced (among HIV+) 
   No 562 75.3 78 43.3 484 85.5 
   Yes 184 24.7 102 56.7 82 14.5 <0.001 
Abbreviations: HAART, Highly Active Antiretroviral Therapy 
aPearson’s χ2 was used for categorical variables. A two-sample Wilcoxon rank-sum (Mann-Whitney) test was used for continuous variables.  
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Table 2. Numbers of Cancers by Cancer Type Among Study Participants 
 
Cancer Type Total ( n = 911) WIHS ( n = 210) MACS ( n = 701) 
No. % No. % No. % 
ADM 508 55.8 43 20.5 465 66.3 
   NHL 124 32 92 
   KS 380 7 373 
   ICC 4 4 N/A 
NADM - Infection-related 88 9.7 25 11.9 63 9.0 
   Anal 25 4 21 
   Liver 12 3 9 
   Stomach 3 2 1 
   Vaginal 1 1 N/A 
   Vulvar 2 2 N/A 
   Oral Cavity and Pharynx 13 6 7 
   Hodgkin's Lymphoma 12 5 7 
   NHL, HIV(-) 10 2 8 
   KS, HIV(-) 10 0 10 
NADM - Non-Infection-related 293 32.2 132 62.9 161 23.0 
   Colon 16 7 9 
   Rectum 11 2 9 
   Pancreas 5 3 2 
   Lung 52 38 14 
   Bones/Joints 1 0 1 
   Soft Tissue incl. heart 4 2 2 
   Melanoma 29 4 25 
   Other Non-Epithelial Skin Cancer 2 0 2 
   Breast 41 41 N/A 
   Uterus 6 6 N/A 
   Ovary 1 1 N/A 
   Prostate 54 N/A 54 
   Testis 4 N/A 4 
   Urinary Bladder 7 1 6 
   Kidney and Renal Pelvis 7 3 4 
   Brain/CNS 7 4 3 
   Thyroid/Pituitary 5 3 2 
   Myeloma 10 3 7 
   Leukemia 11 4 7 
   Nose, Nasal Cavity, and Middle Ear 2 0 2 
   Other Endocrine incl. thymus 2 0 2 
   Esophagus 2 0 2 
   Larynx 9 7 2 
   Ureter 1 0 1 
   Small Intestine 2 1 1 
   Gallbladder 2 2 0 
Misc. 22 2.4 10 4.8 12 1.7 













Figure 2. 10-Year Unadjusted Cancer Survival Plot by HAART Era and HIV Status in 
the MACS  
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Figure 3.  A) 5-Year Unadjusted Cancer Survival Plot by HAART Era and HIV Status in 
the MACS, B) Plot of the Relative Hazard as a Function of Time Comparing Survival for 
HIV+ participants diagnosed with cancer in the pre-HAART Era (HIV+, PH) relative to 
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Table 3. Univariable Cox Proportional Hazards Models of Mortality Comparing Cancer 
Survival Among HIV-infected and –uninfected Individuals Diagnosed with Cancer in the 
pre-HAART (1984-1994) and the HAART (1995-2013) Eras  
 
HR 95% CI 
 
p-valuea 
HIV Infection     
   No REF    
   Yes 4.35 3.05, 6.21  <0.001 
Era     
   Pre-HAART REF    
   HAART 0.21 0.16, 0.27  <0.001 
Age (years) 
       < 30 1.18 0.95, 1.46 
 
0.13 
   30 - 39 1.76 1.24, 2.49 
 
0.001 
   40 - 49 REF 
      50 - 59 0.39 0.27, 0.55 
 
<0.001 




       White, non-Hispanic REF 
      Black, non-Hispanic 0.68 0.47, 0.98 
 
0.04 




       Never/Former REF 




       Normal (18.5 – 24.9) REF 
      Underweight ( < 18.5) 1.57 0.95, 2.59 
 
0.08 




       Never/Former REF 
      Current 1.28 1.04, 1.57 
 
0.02 
Prior AIDS Diagnosis 
       No  REF 
      Yes 2.69 2.15, 3.36 
 
<0.001 
Viral Load (cp/ml) 
       < 10,000 REF 
      > 10,000 5.10 3.91, 6.64 
 
<0.001 
Nadir CD4 Cell Count (cells/μl)  
       > 200 REF 
      < 200 3.37 2.72, 4.17 
 
<0.001 
Abbreviations: IDU, intravenous drug user; BMI, body mass index (kg/m2) 




Table 4. Multivariable Cox Proportional Hazards Model of Mortality Comparing Cancer 
Survival Among HIV-infected and –uninfected Individuals Diagnosed with Cancer in the 







HIV Status and Era 
        HIV(-), HAART Era REF 















Interaction with time for HIV(+), pre-HAART Era 1.70 1.39, 2.07 <0.001 
Age (years) 
        < 30 REF 





















         White, non-Hispanic REF 











         Never/Former REF 






         Normal (18.5 – 24.9) REF 











         Never/Former REF 





Prior AIDS Diagnosis 
        No  REF 





Viral Load (cp/ml) 
        < 10,000 REF 





Nadir CD4 Cell Count (cells/μl)  
        > 200 REF 





Abbreviations: IDU, intravenous drug user; BMI, body mass index (kg/m2) 
aPearson’s χ2 was used for categorical variables. 
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Figure 4. 5-Year Unadjusted Cancer Survival Plot by HAART Era and Cancer Type 
Among HIV-infected participants in the MACS, B) Plot of the Relative Hazard as a 
Function of Time Comparing Survival for Participants Diagnosed with ADMs in the pre-
HAART Era (ADM, PH) relative to Participants Diagnosed with NADMs in the HAART 




Abbreviations: NADM, Non-AIDS-Defining Malignancy; ADM, AIDS-Defining Malignancy; HE, 
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Table 5. Univariable Cox Proportional Hazards Models of Mortality Comparing Cancer 
Survival Among HIV-infected Individuals Diagnosed with Cancer in the pre-HAART 
(1984-1994) and the HAART (1995-2013) Eras 
 
HR 95% CI 
 
p-valuea 
Cancer Type    
   NADM REF    
   ADM 4.70 3.17, 6.97  <0.001 
Cancer Type     
   Non-Infection-Related REF    
   Infection-Related 4.41 2.67, 7.29  <0.001 
Era     
   Pre-HAART REF    
   HAART 0.22 0.16, 0.30  <0.001 
Age (years) 
       < 30 1.08 0.86, 1.34 
 
0.51 
   30 - 39 1.59 1.11, 2.28 
 
0.01 
   40 - 49 REF 
      50 - 59 0.43 0.28, 0.64 
 
<0.001 




        White, non-Hispanic REF 
      Black, non-Hispanic 0.63 0.41, 0.95 
 
0.03 




        Never/Former REF 




        Normal (18.5 – 24.9) REF 
      Underweight ( < 18.5) 1.63 0.99, 2.70 
 
0.06 




        Never/Former REF 
      Current 1.04 0.84, 1.30 
 
0.70 
Prior AIDS Diagnosis 
       No  REF 
      Yes 2.11 1.68, 2.64 
 
<0.001 
Viral Load (cp/ml) 
       < 10,000 REF 
      > 10,000 4.83 3.34, 7.00 
 
<0.001 
Nadir CD4 Cell Count (cells/μl)  
       > 200 REF 
      < 200 2.58 2.02, 3.29 
 
<0.001 
Abbreviations: IDU, intravenous drug user; BMI, body mass index (kg/m2) 
aPearson’s χ2 was used for categorical variables. 
 
 49 
Table 6. Multivariable Cox Proportional Hazards Model of Mortality Comparing Cancer 
Survival Among HIV-infected Individuals Diagnosed with Non-AIDS-Defining 
Malignancies (NADMs) and AIDS-Defining Malignancies (ADMs) in the pre-HAART 
(1984-1994) and the HAART (1995-2013) Eras 
 
HR 95% CI 
 
p-valuea 
Cancer Type and Era 
       NADM, HAART era REF 
      ADM, HAART era 2.12 1.08, 4.15 
 
0.03 
   NADM, pre-HAART era 4.91 2.12, 11.39 
 
<0.001 
   ADM, pre-HAART era 2.54 1.22, 5.30 
 
0.01 
Interaction with time for ADM, pre-HAART era 1.74 1.38, 2.19 <0.001 
Age (years) 
       < 30 REF  
      30 - 39 0.76 0.53, 1.09 
 
0.13 
   40 - 49 0.89 0.61, 1.28 
 
0.52 
   50 - 59 0.83 0.48, 1.42 
 
0.50 




        White, non-Hispanic REF 
      Black, non-Hispanic 1.00 0.65, 1.54 
 
1.00 




        Never/Former REF 




        Normal (18.5 – 24.9) REF 
      Underweight ( < 18.5) 1.51 0.90, 2.53 
 
0.12 




        Never/Former REF 
      Current 1.33 1.06, 1.66 
 
0.01 
Prior AIDS Diagnosis 
       No  REF 
      Yes 1.83 1.44, 2.34 
 
<0.001 
Viral Load (cp/ml) 
       < 10,000 REF 
      > 10,000 1.38 0.85, 2.21 
 
0.19 
Nadir CD4 Cell Count (cells/μl)  
       > 200 REF 
      < 200 2.35 1.79, 3.08 
 
<0.001 
Abbreviations: IDU, intravenous drug user; BMI, body mass index (kg/m2) 





Figure 5. A) 5-Year Unadjusted Cancer Survival Plot by HAART Era and Cancer Type 
(Infection-Related or Non-Infection-Related) Among HIV-infected participants in the 
MACS, B) Plot of the Relative Hazard as a Function of Time Comparing Survival for 
Participants Diagnosed with Infection-Related Cancers in the pre-HAART Era (Inf, PH) 
relative to Participants Diagnosed with Non-Infection-Related Cancers in the HAART 




Abbreviations: Non-Inf, Non-Infection-Related Cancer; Inf, Infection-Related Cancer; HE, HAART Era; 
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Table 7. Multivariable Cox Proportional Hazards Model of Mortality Comparing Cancer 
Survival Among HIV-infected Individuals Diagnosed with Infection-Related Cancers and 
Non-Infection-Related Cancers in the pre-HAART (1984-1994) and the HAART (1995-




95% CI p-valuea 
Cancer Type and Era 
       Non-Infection-Related, HAART era REF 
      Infection-Related, HAART era 1.89 
 
0.81, 4.39 0.14 
   Non-Infection-Related, pre-HAART era 6.56 
 
2.33, 18.48 <0.001 
   Infection-Related, pre-HAART era 2.48 
 
0.98, 6.29 0.06 
Interaction with time for infection-related, pre-
HAART 1.72  1.36, 2.18 <0.001 
Age (years) 
       < 30 REF 
      30 - 39 0.76 
 
0.54, 1.09 0.14 
   40 - 49 0.88 
 
0.61, 1.28 0.51 
   50 - 59 0.79 
 
0.46, 1.36 0.39 
   60 + 0.59 
 
0.17, 2.08 0.41 
Race 
        White, non-Hispanic REF 
      Black, non-Hispanic 0.95 
 
0.62, 1.46 0.82 
   Other 1.23 
 
0.87, 1.76 0.24 
IDU 
        Never/Former REF 
      Current 0.71 
 
0.29, 1.78 0.47 
BMI 
        Normal (18.5 – 24.9) REF 
      Underweight ( < 18.5) 1.53 
 
0.91, 2.57 0.11 
   Overweight/Obese (25.0 +) 0.75 
 
0.57, 0.99 0.04 
Smoking History 
        Never/Former REF 
      Current 1.32 
 
1.05, 1.65 0.02 
Prior AIDS Diagnosis 
       No  REF 
      Yes 1.81 
 
1.42, 2.31 <0.001 
Viral Load (cp/ml) 
       < 10,000 REF 
      > 10,000 1.57 
 
0.98, 2.51 0.06 
Nadir CD4 Cell Count (cells/μl)  
       > 200 REF 
      < 200 2.38 
 
1.82, 3.12 <0.001 
Abbreviations: IDU, intravenous drug user; BMI, body mass index (kg/m2) 




Figure 6. 5-Year Unadjusted Cancer Survival Plot by HIV Status and HAART Use 
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Table 8. Univarible Cox Proportional Hazards Models of Mortality Comparing Cancer 
Survival Use Among HIV-infected and –uninfected MACS and WIHS participants in the 
HAART (1995-2013) Era 
 
HR 95% CI p-valuea 
HIV Infection    
   No REF   
   Yes 2.42 1.68, 3.49 <0.001 
HAART Experienced    
   No REF   
   Yes 1.12 0.87, 1.46 0.38 
Age (years) 
      < 30 0.82 0.56, 1.19 0.29 
   30 - 39 1.20 0.44, 3.27 0.72 
   40 - 49 REF 
     50 - 59 0.80 0.59, 1.09 0.16 
   60 + 0.42 0.26, 0.67 <0.001 
Race 
       White, non-Hispanic REF 
     Black, non-Hispanic 2.51 1.87, 3.37 <0.001 
   Other 2.14 1.46, 3.14 <0.001 
IDU 
       Never/Former REF 
     Current 1.89 0.93, 3.83 0.08 
BMI 
       Normal (18.5 – 24.9) REF 
     Underweight ( < 18.5) 2.64 1.65, 4.24 <0.001 
   Overweight/Obese (25.0 +) 0.83 0.63, 1.08 0.17 
Smoking History 
       Never/Former REF 
     Current 2.16 1.66, 2.82 <0.001 
Prior AIDS Diagnosis 
      No  REF 
     Yes 2.72 2.10, 3.53 <0.001 
Viral Load (cp/ml) 
      < 10,000 REF 
     > 10,000 1.86 1.43, 2.43 <0.001 
Nadir CD4 Cell Count (cells/μl)  
      > 200 REF 
     < 200 1.94 1.49, 2.51 <0.001 
Abbreviations: IDU, intravenous drug user; BMI, body mass index (kg/m2) 






Table 9. Multivariable Cox Proportional Hazards Model of Mortality Comparing Cancer 
Survival by HIV Status and HAART Use Among MACS and WIHS participants in the 
HAART (1995-2013) Era 
 
HR 95% CI 
 
p-valuea 
HIV Status and HAART Use 
       HIV(-) REF 
      HIV(+) using HAART 0.92 0.57, 1.48 
 
0.72 




       < 30 REF 
      30 - 39 0.97 0.33, 2.86 
 
0.96 
   40 - 49 1.26 0.44, 3.57 
 
0.67 
   50 - 59 1.38 0.48, 3.96 
 
0.56 




        White, non-Hispanic REF 
      Black, non-Hispanic 1.36 0.94, 1.97 
 
0.10 




        Never/Former REF 




        Normal (18.5 – 24.9) REF 
      Underweight ( < 18.5) 1.42 0.86, 2.35 
 
0.17 




        Never/Former REF 
      Current 1.35 1.00, 1.83 
 
0.05 
Prior AIDS Diagnosis 
       No  REF 
      Yes 1.55 1.13, 2.13 
 
0.007 
Viral Load (cp/ml) 
       < 10,000 REF 
      > 10,000 1.15 0.82, 1.60 
 
0.42 
Nadir CD4 Cell Count (cells/μl)  
       > 200 REF 
      < 200 1.44 1.01, 2.04 
 
0.04 
Abbreviations: IDU, intravenous drug user; BMI, body mass index (kg/m2) 
aPearson’s χ2 was used for categorical variables. 





Figure 7. 5-Year Unadjusted Cancer Survival Plot by Cancer Type (ADM vs. NADM) 
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Table 10. Univariable Cox Proportional Hazards Models of Mortality Comparing Cancer 
Survival Among HIV-infected MACS and WIHS participants in the HAART (1995-
2013) Era 
 
HR 95% CI p-valuea 
Cancer Type    
   NADM REF   
   ADM 1.15 0.85, 1.55 0.36 
Cancer Type    
   Non-Infection-Related REF   
   Infection-Related 1.01 0.75, 1.34 0.96 
HAART Experienced    
   No REF   
   Yes 0.74 0.56, 0.99 0.04 
Age (years) 
      < 30 0.81 0.55, 1.20 0.29 
   30 - 39 1.70 0.54, 5.39 0.37 
   40 - 49 REF 
     50 - 59 0.82 0.58, 1.16 0.25 
   60 + 0.56 0.29, 1.04 0.07 
Race 
       White, non-Hispanic REF 
     Black, non-Hispanic 2.25 1.61, 3.14 <0.001 
   Other 1.72 1.12, 2.64 0.01 
IDU 
       Never/Former REF 
     Current 1.85 0.91, 3.76 0.09 
BMI 
       Normal (18.5 – 24.9) REF 
     Underweight ( < 18.5) 2.49 1.50, 4.16 <0.001 
   Overweight/Obese (25.0 +) 0.85 0.63, 1.15 0.30 
Smoking History 
       Never/Former REF 
     Current 1.62 1.21, 2.16 0.001 
Prior AIDS Diagnosis 
      No  REF 
     Yes 2.42 1.80, 3.24 <0.001 
Viral Load (cp/ml) 
      < 10,000 REF 
     > 10,000 1.57 1.18, 2.10 0.002 
Nadir CD4 Cell Count (cells/μl)  
      > 200 REF 
     < 200 1.65 1.22, 2.23 0.001 
Abbreviations: IDU, intravenous drug user; BMI, body mass index (kg/m2) 




Table 11. Multivariable Cox Proportional Hazards Model of Mortality Comparing 
Cancer Survival by Cancer Type (ADM vs. NADM) and HAART Use Among HIV-
infected MACS and WIHS participants in the HAART (1995-2013) Era 
 




       NADM REF 




       No REF 




       < 30 REF 
      30 - 39 0.76 0.22, 2.70 
 
0.68 
   40 - 49 1.10 0.31, 3.86 
 
0.88 
   50 - 59 1.16 0.32, 4.16 
 
0.83 




        White, non-Hispanic REF 
      Black, non-Hispanic 1.66 1.09, 2.52 
 
0.02 




        Never/Former REF 




        Normal (18.5 – 24.9) REF 
      Underweight ( < 18.5) 1.36 0.79, 2.37 
 
0.27 




        Never/Former REF 
      Current 1.08 0.77, 1.51 
 
0.67 
Prior AIDS Diagnosis 
       No  REF 
      Yes 1.68 1.20, 2.35 
 
0.002 
Viral Load (cp/ml) 
       < 10,000 REF 
      > 10,000 1.00 0.68, 1.47 
 
1.00 
Nadir CD4 Cell Count (cells/μl)  
       > 200 REF 
      < 200 1.53 1.05, 2.22 
 
0.03 
Abbreviations: IDU, intravenous drug user; BMI, body mass index (kg/m2) 
aPearson’s χ2 was used for categorical variables. 





Figure 8. 5-Year Unadjusted Cancer Survival Plot by Cancer Type (infection-related vs. 
non-infection related) and HAART Use Among HIV-infected MACS and WIHS 
participants in the HAART Era 
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Table 12. Multivariable Cox Proportional Hazards Model of Mortality Comparing 
Cancer Survival by Cancer Type (infection-related vs. non-infection-related) and 








        Non-Infection-Related REF 






        No REF 












        < 30 REF 





















         White, non-Hispanic REF 











         Never/Former REF 






         Normal (18.5 – 24.9) REF 











         Never/Former REF 





Prior AIDS Diagnosis 
        No  REF 





Viral Load (cp/ml) 
        < 10,000 REF 





Nadir CD4 Cell Count (cells/μl)  
        > 200 REF 





Abbreviations: IDU, intravenous drug user; BMI, body mass index (kg/m2) 
aPearson’s χ2 was used for categorical variables. 




Table 13. Adjusted Cox Proportional Hazards Ratios of Mortality Comparing Cancer 
Survival by Cancer Type (infection-related vs. non-infection-related) and HAART Use 







HAART Users (REF) to Non-Users 










Infection-Related (REF) to Non-Infection-
Related 










aPearson’s χ2 was used for categorical variables. 
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